GW Pharmaceuticals PLC- (GWPH) Downgraded to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a buy rating to a hold rating in a report issued on Tuesday morning. They currently have $161.00 target price on the biopharmaceutical company’s stock.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

Other equities research analysts also recently issued research reports about the company. ValuEngine upgraded GW Pharmaceuticals PLC- from a buy rating to a strong-buy rating in a report on Thursday, November 1st. Piper Jaffray Companies restated an overweight rating on shares of GW Pharmaceuticals PLC- in a report on Monday. BidaskClub upgraded GW Pharmaceuticals PLC- from a sell rating to a hold rating in a report on Saturday, August 11th. Bank of America restated a buy rating and set a $197.00 price objective (up previously from $181.00) on shares of GW Pharmaceuticals PLC- in a report on Friday, September 28th. Finally, Morgan Stanley boosted their price objective on GW Pharmaceuticals PLC- from $197.00 to $240.00 and gave the company an overweight rating in a report on Friday, September 28th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $184.13.

Shares of GWPH opened at $142.67 on Tuesday. GW Pharmaceuticals PLC- has a 52-week low of $105.12 and a 52-week high of $179.65. The company has a current ratio of 8.67, a quick ratio of 8.21 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $4.39 billion, a price-to-earnings ratio of -20.53 and a beta of 2.25.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%. The firm had revenue of $3.46 million for the quarter, compared to analyst estimates of $2.00 million. Equities analysts predict that GW Pharmaceuticals PLC- will post -9.14 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harvest Management LLC bought a new stake in shares of GW Pharmaceuticals PLC- during the third quarter valued at approximately $207,000. Commonwealth Equity Services LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 23.3% during the third quarter. Commonwealth Equity Services LLC now owns 19,106 shares of the biopharmaceutical company’s stock valued at $3,300,000 after acquiring an additional 3,606 shares in the last quarter. C WorldWide Group Holding A S increased its holdings in shares of GW Pharmaceuticals PLC- by 7.0% during the third quarter. C WorldWide Group Holding A S now owns 34,088 shares of the biopharmaceutical company’s stock valued at $5,888,000 after acquiring an additional 2,230 shares in the last quarter. Private Advisor Group LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 94.9% during the third quarter. Private Advisor Group LLC now owns 5,603 shares of the biopharmaceutical company’s stock valued at $968,000 after acquiring an additional 2,728 shares in the last quarter. Finally, Scott & Selber Inc. bought a new stake in shares of GW Pharmaceuticals PLC- during the third quarter valued at approximately $2,745,000. Hedge funds and other institutional investors own 70.02% of the company’s stock.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Article: What is a put option?

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply